Form 4: Amgen SVP Rachna Khosla Reports Stock Disposition

Amgen Inc. SVP of Business Development Rachna Khosla disposed of 93 shares of common stock to cover tax obligations.

Summary

• Rachna Khosla, SVP of Business Development at Amgen Inc., disposed of 93 shares of common stock.
• The transaction occurred on May 7, 2026, at a price of $331.11 per share.
• The disposition was executed via transaction code 'F', indicating the payment of tax liability by delivering or withholding securities.
• Following this transaction, the reporting person maintains beneficial ownership of 8,394 shares of Amgen common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction is a mandatory tax-related disposition rather than a market-driven sale.

Positives

• The transaction was a routine administrative action related to tax withholding rather than a discretionary sale of equity.

Negatives

• Reduction in the total number of shares held directly by a key executive.

Risks

• None identified; this is a standard regulatory disclosure for executive compensation tax compliance.

Future Outlook

Not applicable; this is a historical disclosure of a past transaction.

Industry Context

StockSavvy.ai notes that routine Form 4 filings involving tax withholding are standard practice for executives in the biotechnology sector and do not typically signal changes in corporate strategy or executive sentiment.

Comparison to Industry Standards

• The transaction aligns with standard executive equity management practices observed at large-cap pharmaceutical companies like Pfizer, Gilead, and AbbVie.

Stakeholder Impact

• Minimal impact on shareholders as the transaction represents a small fraction of the executive's total holdings.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Trading, Executive Compensation, Biotechnology